Evidence map›Paper›PMID 35356635›Full record

ArticleJournal of hematology2022

Consensus Statement: Importance of Timely Access to Multiple Myeloma Diagnosis and Treatment in Central America and the Caribbean.

Mayra Pimentel, Ondina Espinal, Francisco Godinez, Fabian Jimenez, Darwin Martinez, Ninotchka Mendoza, Anarellys Quintana, Juan Enrique Richmond, Esmedalys Romero

Abstract read
In one paragraph

Article in Journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mayra PimentelDepartment of Hematology, Instituto Nacional del Cancer Rosa Emilia Tavares, Santo Domingo, Dominican Republic.
Ondina EspinalDepartment of Hematology, Hospital Jose Maria Cabral and Clinica Corominas, Santiago De Los Caballeros, Dominican Republic.
Francisco GodinezDepartment of Hematology, Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala.
Fabian JimenezDepartment of Hematology, Hospital San Juan de Dios, San Jose, Costa Rica.
Darwin MartinezDepartment of Hematology, Hospital Escuela and Instituto Hondureno de Seguridad Social, Tegucigalpa, Honduras.
Ninotchka MendozaComplejo Hospitalario Doctor Arnulfo Arias Madrid, Panama City, Panama.
Anarellys QuintanaPanamanian Society of Hematology, Panama City, Panama.
Juan Enrique RichmondDepartment of Hematology-Oncology, Hospital Calderon Guardia, Universidad de Costa Rica, San Jose, Costa Rica.
Esmedalys RomeroDepartment of Hematology, Hospital Salvador de Gautier, Centro Medico Moderno, Dominican Society of Hematology, Santo Domingo, Dominican Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In Central America and the Caribbean, multiple myeloma (MM) patients face significant barriers to diagnosis and treatment. The aim of this study is to describe the current situation of MM in the region, discuss the current barriers to timely diagnosis and proper treatment, and develop consensus recommendations to address these issues. Methods: Nine experts from five countries took part in a virtual consensus meeting on MM in Central America and the Caribbean. During the meeting, experts analyzed the disease burden, the current conditions for disease management, and access to treatment in the region. The participants reached a consensus on the extent of the problem and the necessary measures. Results: Hard evidence on the incidence and prevalence of MM in the region is scarce, but the experts perceive an increase in MM cases. The lack of data on the direct and indirect costs at the local and regional levels obscures the impact of the disease and limits awareness among decision-makers. Most patients are diagnosed late and face long waiting times and geographical barriers to access treatment. Access to efficacious innovative therapies that increase survival time is limited due to access barriers within health systems. Conclusions: There was consensus on five recommendations: 1) to generate evidence; 2) to educate the public; 3) to increase timely diagnosis and facilitate access to treatment; 4) to promote interaction, collaboration, and participation among all sectors involved in the decision-making process; and 5) to guarantee timely access to new therapies.

Indexed as

Cytogenetics and molecular geneticsLymphocytesMultiple myelomaMyelodysplastic syndromesStem cell transplantation

Identifiers

PMID35356635
PMCPMC8929200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.